Nutriband Inc. Scales Manufacturing for Global Commercialization of Abuse-Deterrent Fentanyl Patch

Nutriband Inc. (NASDAQ: NTRB) has achieved significant manufacturing scale-up for its AVERSA™ abuse-deterrent technology, positioning the company for global commercialization of its innovative fentanyl patch. The technology incorporates aversive agents into transdermal patches to prevent misuse, abuse, diversion, and accidental exposure of drugs with abuse potential. This development comes as the company prepares for submission to regulatory authorities, including the FDA, which could unlock substantial revenue opportunities in the pharmaceutical market.

The company has established a comprehensive global intellectual property protection strategy, securing patents across multiple jurisdictions including the United States, Europe, Asia, and Australia. This robust IP portfolio protects Nutriband's innovative approach to addressing the opioid crisis through technological solutions that make powerful medications safer for legitimate use while deterring misuse. The manufacturing scale-up has been achieved through collaboration with Kindeva, a leading contract development and manufacturing organization specializing in transdermal drug delivery systems.

Nutriband's AVERSA technology represents a significant advancement in transdermal pharmaceutical products, as it can be incorporated into any transdermal patch containing drugs with abuse potential. The technology works by including aversive agents that activate when someone attempts to misuse the medication, creating unpleasant effects that deter abuse while maintaining therapeutic efficacy for legitimate patients. This approach addresses a critical need in pain management, where fentanyl patches have been subject to misuse despite their medical importance.

The company's progress toward FDA submission marks a pivotal moment in its development pathway, potentially transitioning Nutriband from a development-stage company to a commercial entity. Successful regulatory approval could position AVERSA technology as a standard for abuse-deterrent transdermal medications, creating value for shareholders while contributing to public health efforts against opioid abuse. More information about the company's technology and development progress is available at https://www.nutriband.com.

Investors and stakeholders can access the latest updates and news regarding Nutriband's developments through the company's dedicated newsroom at https://ibn.fm/NTRB. The scaling of manufacturing capabilities and preparation for regulatory submissions demonstrate Nutriband's commitment to bringing its abuse-deterrent technology to market, addressing both medical needs and public health concerns surrounding opioid medications.